Skip to content

Author

Mei Wang

We have 3 of 24 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Structure-guided discovery of HIV-1 capsid inhibitors: From diverse binding sites to resistance-resilient antiviral strategies.

This review covers 2020-2026 advances in CA-targeted drug discovery: high-resolution CA structures; allosteric regulation by host metabolite IP6; medicinal chemistry optimization of PF74 derivatives via scaffold hopping and conformational restriction to enhance potency and metabolic stability; the development and clini...

Yu-Ya Li, Mei Wang, Lin Sun et al. · 0 citations
Aug 2026

Discovery of piperazine-based multi-site occupying coronavirus Mpro inhibitors with potent and broad-spectrum antiviral activity.

The discovery and optimization of a novel series of piperazine-based Mpro inhibitors using a multi-site binding strategy guided by analysis of conserved residues within the coronavirus Mpro active sites are reported, highlighting the utility of structure-based design for the development of promising broad-spectrum anti...

Bing Ye, Myoung Kyu Lee, Letian Song et al. · 0 citations
Jul 2026

Targeted Degradation of Capsid by Host-Hijacking PROTAC Overcomes Drug Resistance.

This work pioneers the development of CA-targeted degraders, providing a framework for next-generation anti-HIV therapies with high potency and resistance barriers, via a proteasome-driven pathway.

Mei Wang, Ze-Yu Peng, Yang Zhou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.